Basic Information
Prexton Therapeutics focuses on developing novel compound drugs for the treatment of central nervous system (CNS) diseases. The company was founded in 2012 by its current CEO, Mr. Francois Conquet, and Merck Ventures. It adopts a completely new scientific approach, fully integrating molecular biology, behavioral science, and chemical technologies to address Parkinson's disease and other brain disorders.
Prexton Therapeutics BV
Netherlands
less than 15 people
January 01, 2012
--
info@prextontherapeutics.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios